Overview

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Status:
Recruiting

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL who have not been treated. Participation could last up to five years.

Phase:

Phase 3

Details

Lead Sponsor:

Loxo Oncology, Inc.

Treatments:

Bendamustine Hydrochloride
Rituximab